To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
September 2014
Kidney transplantation
A randomized, prospective, parallel group study of laparoscopic versus laparoendoscopic single site donor nephrectomy for kidney donation.
Aull M J, Afaneh C, et al. American Journal of Transplantation. 2014; 14(7): 1630-1637.
Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
Charpentier B, Medina Pestana JO, et al. American Journal of Transplantation 2013; 13(11): 2884-2891.
Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial.
Hart A, Jackson S, et al. Transplantation 2014; 97(10): 1066-1071.
Home-based family intervention increases knowledge, communication and living donation rates: a randomized controlled trial.
Ismail SY, Luchtenburg AE, et al. American Journal of Transplantation. 2014; 14(8): 1862-1869.
Liver transplantation
High-throughput sequencing analysis of post-liver transplantation HCV e2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.
Babcock G J, Iyer S, et al. PLoS ONE [Electronic Resource] 2014 9(6): e100325.
The effect of remote ischemic post-conditioning in patients undergoing living donor liver transplantation.
Kim WH, Lee JH, et al. Liver Transplantation 2014; 20(11): 1383-1392
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.
Klintmalm GB, Feng S, et al. American Journal of Transplantation 2014; 14(8): 1817-1827
Heart transplantation
Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation.
Urbanowicz T, Baszynska-Wachowiak H, et al. Annals of Transplantation 2014; 19: 295-299.
Lung transplantation
Development of a predictive model for long-term survival after lung transplantation and implications for the lung allocation score.
Gries C J, Rue TC, et al. Journal of Heart & Lung Transplantation 2010; 29(7): 731-738.
Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.
Jaksch P, Ankersmit J, et al. American Journal of Transplantation 2014; 14(8): 1839-1845